Abbott Laboratories Corporation

Eli Lilly and Company

Yihong Li

Yun He

Nan-Horng Lin

Mark W Holladay

Keith Brian Ryther

James Robert Henry

Timothy Paul Burkholder

Sushant Malhotra

Hao Bai

Joshua Ryan Clayton

Thomas Albert Engler

Kelly Wayne Furness

Brian Raymond Berridge

Charles Edward Ruegg

John Morris Sullivan

Gang Liu

Pamela Ann Albaugh

Jon Kevin Reel

Michael J Dart

Jerome F Daanen

Zhonghua Pei

David Mendel

Guoxin Zhu

Scott Eugene Conner

Mark Joseph Tebbe

Johnathan Alexander McLean

Angela Lynn Marquart

James T Wasicak

Richard L Elliott

David A Janowick

Clive Gideon Diefenbacher

Brian Eugene Cunningham

Jochen Ammenn

The present invention provides kinase inhibitors of Formula I. 

Purine derivatives as kinase inhibitors

The present invention provides kinase inhibitors of Formula (I) 

Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors

The present invention is directed to compounds of the structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof: Formula I (a) R1, R2 and R6 are each independently selected from the group consisting of hydrogen, C-Calkyl substituted C-Calkyl, aryl-C-alkyl, substituted aryl-C-alkyl, heteroaryl-C-alkyl, substituted heteroaryl-C-alkyl, C-Ccycloalkylaryl-C-alkyl, and substituted C-Ccycloalkylaryl-C-alkyl; (b) X is an optionally substituted C-Calkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S; (c) Y is C, O, S, NH or a single bond; and (d) E is selected from the group consisting of hydrogen, C(R3)(R4)A, A, (CH)COOR19 and substituted (CH)COOR19.

Urea linker derivatives for use as PPAR modulators

Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors

3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission

Novel 3-pyridyloxymethyl heterocyclic ether compounds of the formula: ##STR1## or the pharmaceutically-acceptable salts or prodrugs thereof are selective and potent ligands at neuronal nicotinic cholinergic channel receptors, and are effective in controlling synaptic transmission. Key intermediates and processes using this key intermediates to produce compounds of formula I with the variables defined in the specification are also described.

3-Pyridyloxymethyl heterocyclic ether compounds useful in controlling

Novel heterocyclic ether compounds having the formula: ##STR1## wherein A, m, R, X, Y.sup.1, Y.sup.2 and Y.sup.3 are specifically defined, which are useful in selectively controlling chemical synaptic transmission; therapeutically-effective pharmaceutical compositions thereof; and use of said compositions to selectively control synaptic transmission in mammals.

Furopyridine, thienopyridine pyrrolopyridine useful in controlling

Novel 3-pyridyloxymethyl heterocyclic ether compounds of the formula: ##STR1## or the pharmaceutically-acceptable salts or prodrugs thereof are selective and potent ligands at neuronal nicotinic cholinergic channel receptors, and are effective in controlling synaptic transmission.

3-pyridyloxymethyl heterocyclic ether compounds useful in controlling

Growing community of inventors

Carmel, IN, United States of America

Yihong Li